Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.
about
Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunityHigh efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model.Ethnic disparities in cancer incidence among residents of GuamCombination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.Therapeutic and prophylactic applications of alphavirus vectors.Acute infection with venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challengeGenome-wide RNAi screen identifies SEC61A and VCP as conserved regulators of Sindbis virus entry.Alphavirus-based vaccines encoding nonstructural proteins of hepatitis C virus induce robust and protective T-cell responses.Salmonella typhimurium stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model.Comparative protein profiling of B16 mouse melanoma cells susceptible and non-susceptible to alphavirus infection: Effect of the tumor microenvironment.A plasmid-based reverse genetics system for animal double-stranded RNA viruses.A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.Respiratory syncytial virus vaccine development
P2860
Q28749317-4255F388-B310-43C2-8D5A-47E81360A631Q33828697-4B4D57BB-3685-4734-8AC3-65969DA8AF01Q35272221-E19855D7-2B8C-41AE-967D-A7392E6A1CB8Q35527105-33DB2E60-7320-4DD7-81DF-A7312049CAFDQ36716920-1F3A8A0E-D859-441C-8880-BB5B206A2D33Q37322650-A42D5C8E-B015-4DE4-8FD3-161D5E24D24AQ37451959-3794B43D-66D4-417A-93C2-EE680BA0C4A2Q37576241-94891B86-8B2B-4E89-9ACE-9E84618412C7Q37696017-5CE637E9-7EB1-4AFD-A572-4DC9DD40B75DQ40141190-05ABE4AB-E93E-44A6-9EF3-8D55FA77FE29Q40537831-412128A1-D23D-483B-A10A-AE4373C3F524Q42084718-EE0822A8-C476-45F2-912C-A2DEB4B94041Q45399754-59810966-990F-418B-AF0F-0D3A9FAD5751Q45872770-A3F24149-A4D0-4E13-8EA6-AB9A9641F4D5Q56893551-E5E6E082-23C4-485F-B8A0-D381D2B4A71D
P2860
Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.
@ast
Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.
@en
type
label
Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.
@ast
Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.
@en
prefLabel
Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.
@ast
Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.
@en
P2093
P50
P1476
Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.
@en
P2093
Annelies Riezebos-Brilman
Arjan de Mare
Laura Bungener
P304
P356
10.1016/J.JCV.2005.12.001
P577
2006-01-30T00:00:00Z